Introduction: Statins are pharmacological agents commonly used to lower serum cholesterol level. The aim of the experiment was to investigate the effect of the statin simvastatin on thrombopoiesis in the porcine model because it is the closest to the human one regarding physiological and genetic similarities.
Material and Methods: The study was conducted on a group of 32 pigs randomly divided into two equal groups: control and experimental. The pigs were treated for 28 and 56 days with simvastatin in a dose of 40 mg per day per animal. Cytological evaluation of bone marrow smears was performed to assess the average number of all types of cells during thrombopoiesis as was analysis of haematological parameters to assess PLT and MPV.
Results: During the course of the experiment statistically significant changes in the number of promegakaryocytes were observed. Other parameters also showed some fluctuations during the study. However, these changes were not statistically significant.
Conclusion: The obtained results clearly indicate a toxic influence of simvastatin on the process of thrombopoiesis and prove that statins reduce mean platelet volume, thus affecting the process of clot formation through the period of administration in a duration-dependent manner.
1. Antons K.A., Williams C.D., Baker S.K., Philips P.S.: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006, 119, 400–409.
2. Black A.E., Hayes R.N., Roth B.D., Woo P., Woolf T.F.: Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 2000, 27, 916–992.
3. Chello M., Anselmi A., Spadaccio C., Patti G., Goffredo C., Di Sciascio G., Covino E.: Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 2007, 83, 1374–1380.
4. Cui Q., Wang G.J., Su C.C., Balian G.: The Otto Aufranc Award: lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop 1997, 344, 8–19.
5. Edwards C.J., Hart D.J., Spector T.D.: Oral statin and increased bone mineral density in postmenopausal women. Lancet 2000, 355, 2218–2219.
6. Gaddam V., Li D.Y., Mehta J.L.: Anti-thrombotic effects of atrovastatin- an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002, 7, 247–253.
7. Glińska K., Nicpoń J., Pawlas M.: Mechanism of action of statins and possibilities of their application in dog therapy. Med Weter 2006, 62, 254–256.
8. Jenne C.N., Kubes P.: Platelets in inflammation and infection. Platelets 2015, 26, 286–292.
9. Martin J.F., Bath P.M.W., Burr M.L.: Influence of platelet size on outcome after myocardial infarction. Lancet 1991, 338, 1409–1411.
10. Martin J.F., Trowbridge E.A., Salmon G., Plumb J..: The biological significance of platelet volume: its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983, 32, 443–460.
11. Motawi T.M., Atta H.M., Sadik N.A., Azzam M..: The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis. Cell Biochem Biophys 2014, 68, 111–25.
12. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286, 1946–1949.
13. Newman A., Clutterbuck R.D., Powles R.L., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G.: Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia 1994, 8, 2023–2029.
14. Owens A.P. 3rd, Mackman N.: The antithrombotic effects of statins. Annu Rev Med 2014, 65, 433–445.
15. Pagkalos J., Cha J.M., Kang Y., Heliotis M., Tsiridis E., Mantalaris A.: Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 2010, 25, 2470–2478.
16. Puccetti L., Bruni F., Bova G., Cercignani M., Pompella G., Auteri A., Pasqui A.L.: Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolaemia subjects. In vivo effect of cerivastatin. Int J Clin Lab Res 2000, 30, 147–156.
17. Puccetti L., Pasqui A.L., Auteri A., Bruni F.: Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5, 121–126.
18. Puccetti L., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., Angori P., Auteri A., Bruni F.: Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002, 32, 901–908.
19. Rodriguez A.L., Wójcik B.M., Wróbleski S.K., Myers D.D. Jr, Wakefield T.W., Diaz J.A.: Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012, 33, 371–382.
20. Sikora J., Kostka B., Marczyk I., Krajewska U., Chałubiński M., Broncel M.: Effect of statins on platelet function in patients with hyperlipidemia. Arch Med Sci 2013, 9, 622–628.
21. Sivri N., Tekin G., Yalta K., Aksoy Y., Senen K., Yetkin E.: Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol 2013, 71, 1042–1047.
22. Snarska A., Gonkowski S., Rytel L., Pomianowski A., Babińska I., Otrocka-Domagała I., Żarczyńska K., Wysocka D., Sobiech P.: The influence of simvastatin on red blood cells line in the porcine bone marrow. Pol J Vet Sci 2017, 20, 743–746.
23. Yang Y., Qian H., Huang J., Li J.J., Gao R.L., Dou K.F., Yang G.S., Willerson J.T., Geng Y.J.: Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts Arterioscler Thromb Vasc Biol 2009, 29, 2076–2082.
24. Yetkin E.: Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost 2008, 100, 3–4.